Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00554970 · ClinicalTrials.gov registry record · Phase 2
A Study of 2 Doses of MAP0010 in Adult Asthmatics
A Phase 2 study of Asthma, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT00554970: Completed Phase 2 study of Asthma, sponsored by Allergan.
NCT00554970 is a Phase 2 study of Asthma that has completed, run by Allergan. The registered enrollment target is 32 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00554970, a Phase 2 study of Asthma, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine the blood levels of two doses of MAP0010 (a corticosteroid) and two doses of an approved corticosteroid in adult asthma and safety with twice daily dosing over 7 days.
Primary Outcome
The maximum concentration (Cmax) is the highest concentration of a drug measured in the plasma. Plasma is the clear portion of the blood. The Cmax of Budesonide is reported in picograms per milliliter (pg/ml).
Conditions Studied
Interventions
- DRUG MAP0010 low dose
- DRUG MAP0010 high dose
- DRUG Budesonide inhalation suspension 0.25mg
- DRUG Budesonide inhalation suspension 0.5mg
Study Locations (1)
California
- West Coast Clinical Trials Phase 2-4, LLC - Long Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2007-11 |
| Est. Completion | 2008-03 |
| Phase | Phase 2 |
What the finished NCT00554970 record still lists
NCT00554970 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 4 interventions - of which MAP0010 low dose is the first listed.
NCT00554970 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00554970 about?
NCT00554970 is a clinical study titled "A Study of 2 Doses of MAP0010 in Adult Asthmatics". The purpose of this study is to examine the blood levels of two doses of MAP0010 (a corticosteroid) and two doses of an approved corticosteroid in adult asthma and safety with twice daily dosing over 7 days.
What is the current status of trial NCT00554970?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2007-11. Estimated completion is 2008-03.
What conditions does trial NCT00554970 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT00554970?
The interventions under investigation include: MAP0010 low dose (DRUG), MAP0010 high dose (DRUG), Budesonide inhalation suspension 0.25mg (DRUG), Budesonide inhalation suspension 0.5mg (DRUG).
Who is sponsoring clinical trial NCT00554970?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00554970 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00554970's enrollment target sits among peer trials
32 297th of 374 higher than 75 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia